|
**Overview**: Anti-Saccharomyces cerevisiae IgA IgG Panel**Introduction**: The Anti-Saccharomyces cerevisiae IgA IgG Panel is a diagnostic tool designed to screen for Crohna's disease using serum samples. In India, inflammatory bowel disease (IBD) including Crohna's is rising, with prevalence estimates of 5-10 per 100,000 in urban areas and increasing in rural populations due to westernization of diet, urbanization, and environmental changes. ASCA (anti-Saccharomyces cerevisiae antibodies) IgA and IgG are positive in 50-70 percent of Crohna's cases (higher in ileal disease) and help differentiate from ulcerative colitis. Symptoms include abdominal pain, diarrhea, weight loss, fistulas, and extraintestinal manifestations. High morbidity from underdiagnosis in rural/low-SES patients, limited gastroenterology access, overlap with infectious colitis/TB, and delayed biologics/immunosuppressive therapy leading to complications like strictures or surgery. Per gastroenterology practices aligned with ICMR and Indian Society of Gastroenterology guidelines, the test employs immunoassay for IgA/IgG detection over 1-2 days with high specificity, valuable for supporting Crohna's diagnosis in ambiguous cases. This diagnostic falls under autoimmune screening and targets patients with suspected IBD, addressing accurate detection to guide endoscopy and therapy. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its serum-based approach ensures reliable performance in India's diverse laboratory settings.**Other Names**: ASCA Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: ASCA identified in 1990s; in India, prominence with rising IBD incidence.**Purpose**: The test screens for 2 parameters including ASCA IgA and IgG to guide Crohna's disease assessment, support diagnosis, differentiate from ulcerative colitis.**Test Parameters**: 1. ASCA IgA, 2. ASCA IgG.**Pretest Condition**: No fasting required; patients should report chronic diarrhea, abdominal pain, weight loss, or family IBD history.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on diarrhea, pain, weight loss, extraintestinal symptoms, family IBD history, or TB exposure.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated Crohna's including surgery or malnutrition, benefits of early detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or concurrent infections can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive ASCA indicates likely Crohna's, necessitating further investigation like specialist consultation or endoscopy. Negative may require follow-up if symptoms persist.**Specialist Consultation**: Gastroenterologists should be consulted for case management, treatment planning.**Additional Supporting Tests**: Colonoscopy, fecal calprotectin, or imaging for confirmation.**Test Limitations**: ASCA may be positive in other conditions; comprehensive approach required.**References**: Indian Journal of Gastroenterology 2024, IBD Studies India 2023. |
